GlobeNewswire Inc | Jan 5, 2022 05:47PM EST

January 05, 2022

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that senior leadership plans to present at the following conferences in January.

Conferences:

Event: Longwood Healthcare Leaders Winter Webconference - DetailsTopic 1: Innovation in Cell TherapyFormat: PanelDate: Thursday, January 6, 2022Time: 1:30 PM ETTopic 2: Making a Big Impact With Limited ResourcesFormat: PanelDate: Thursday, January 6, 2022Time: 5:10 PM ET

Event: LifeSci Partners 11^th Annual Corporate Access Event - DetailsTopic 1: Innovative Approaches to Cell Therapy for OncologyFormat: PanelDate: Friday, January 7, 2022Time: 8:30 AM ETTopic 2: Cancer Vaccines: Promises, Promises ? Has Their Day Come?Format: PanelDate: Friday, January 7, 2022Time: 2:00 PM ET

Event: H.C. Wainwright BIOCONNECT Virtual Conference - DetailsTopic: Corporate UpdateFormat: On demand presentationDate: Monday, January 10, 2022Time: 7:00 AM ET

Event: Advanced Therapies Week - DetailsTopic: Add It Up: 3 Things to Consider for Capacity ExpansionFormat: PanelDate: Wednesday, January 26, 2022Time: 5:00 PM ET

About Genocea Biosciences, Inc.Genoceas mission is to identify the right tumor targets to develop life-changing immunotherapies for people suffering from cancer. Our proprietary ATLAS platform can comprehensively profile each patients T cell responses to potential targets, or antigens, on that patients tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, InhibigensTM, that drive pro-tumor immune responses. We have two ATLAS-enabled programs: GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial and GEN-011, our adoptive T cell therapy comprising neoantigen-targeted peripheral cells for which we are conducting a Phase 1/2a clinical trial. In addition to our two clinical programs, we are conducting research in several areas where we believe ATLAS could be a key tool in optimizing antigen selection for therapies across a number of diseases. To learn more, please visit https://www.genocea.com.

Investor Contact: Media Contact:Dan Ferry Sarah O?Connell617-430-7576 soconnell@vergescientific.comdaniel@lifesciadvisors.com